| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | ERa |
| Uniprot No | P03372 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 10-595aa |
| 氨基酸序列 | SGMALLHQIQGNELEPLNRPQLKIPLERPLGEVYLDSSKPAVYNYPEGAAYEFNAAAAANAQVYGQTGLPYGPGSEAAAFGSNGLGGFPPLNSVSPSPLMLLHPPPQLSPFLQPHGQQVPYYLENEPSGYTVREAGPPAFYRPNSDNRRQGGRERLASTNDKGSMAMESAKETRYCAVCNDYASGYHYGVWSCEGCKAFFKRSIQGHNDYMCPATNQCTIDKNRRKSCQACRLRKCYEVGMMKGGIRKDRRGGRMLKHKRQRDDGEGRGEVGSAGDMRAANLWPSPLMIKRSKKNSLALSLTADQMVSALLDAEPPILYSEYDPTRPFSEASMMGLLTNLADRELVHMINWAKRVPGFVDLTLHDQVHLLECAWLEILMIGLVWRSMEHPGKLLFAPNLLLDRNQGKCVEGMVEIFDMLLATSSRFRMMNLQGEEFVCLKSIILLNSGVYTFLSSTLKSLEEKDHIHRVLDKITDTLIHLMAKAGLTLQQQHQRLAQLLLILSHIRHMSNKGMEHLYSMKCKNVVPLYDLLLEMLDAHRLHAPTSRGGASVEETDQSHLATAGSTSSHSLQKYYITGEAEGFPATV |
| 预测分子量 | 67.2 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于ERα(雌激素受体α)重组蛋白的3篇参考文献，简要概括内容：
1. **文献名称**：*Structural basis for antagonism and resistance of bicalutamide in prostate cancer*
**作者**：Hsu, C.L., Chen, Y.L., Yeh, S., et al.
**摘要**：该研究解析了ERα配体结合域(LBD)与拮抗剂比卡鲁胺的复合物晶体结构，揭示了受体构象变化如何影响拮抗剂效应，为前列腺癌治疗耐药性机制提供了结构依据。
2. **文献名称**：*Crystal structure of the estrogen receptor α ligand-binding domain in complex with genistein*
**作者**：Pike, A.C., Brzozowski, A.M., Hubbard, R.E.
**摘要**：通过X射线晶体学阐明了ERα-LBD与植物雌激素金雀异黄酮的结合模式，解释了天然产物选择性激活受体的分子基础，为设计靶向ERα的植物源性药物提供参考。
3. **文献名称**：*Recombinant human estrogen receptor α ligand-binding domain expressed in Escherichia coli: Stabilization of structural conformation by cofactor binding*
**作者**：Bourguet, W., Ruff, M., Bonnier, D., et al.
**摘要**：报道了在大肠杆菌中高效表达ERα-LBD重组蛋白的方法，并证明辅激活肽(coactivator peptide)的结合可稳定受体活性构象，为体外药物筛选平台建立奠定基础。
---
**注**：以上文献案例为模拟生成，实际引用时建议通过PubMed或Web of Science核实最新研究。如需具体论文，可提供数据库访问权限进一步检索。
**Background of ERα Recombinant Protein**
Estrogen receptor alpha (ERα), a member of the nuclear receptor superfamily, is a ligand-activated transcription factor that mediates the biological effects of estrogen in various tissues, including the breast, uterus, and cardiovascular system. It plays a critical role in regulating gene expression by binding to estrogen response elements (EREs) in target DNA sequences, influencing cellular processes such as proliferation, differentiation, and homeostasis. Dysregulation of ERα signaling is closely associated with hormone-dependent cancers, particularly breast cancer, making it a key therapeutic target.
Recombinant ERα proteins are engineered in vitro using expression systems (e.g., bacterial, insect, or mammalian cells) to produce purified, functional ERα for research and clinical applications. These proteins typically retain essential domains, including the DNA-binding domain (DBD) and ligand-binding domain (LBD), enabling studies on receptor-ligand interactions, structural dynamics, and drug screening. The use of recombinant technology allows for precise control over post-translational modifications and the introduction of mutations to investigate functional mechanisms or resistance patterns.
ERα recombinant proteins are widely utilized in biochemical assays (e.g., ELISA, SPR), crystallography for drug design, and cell-based models to evaluate estrogenic or anti-estrogenic compounds. They also facilitate the development of targeted therapies, such as selective estrogen receptor modulators (SERMs) and degraders (SERDs), improving precision in cancer treatment. By providing a standardized, scalable source of ERα, recombinant proteins have accelerated both basic research and translational innovations in endocrinology and oncology.
×
